Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Study on the Efficacy and Mechanism of METTL3 Peptide Inhibitors in Enhancing Anti-tumor Immune Response by Reshaping the Tumor Microenvironment

NCT06762925 is registered in ClinicalTrials.gov with Xijing Hospital as lead sponsor.

NCT NCT06762925
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06762925 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Study on the Efficacy and Mechanism of METTL3 Peptide Inhibitors in Enhancing Anti-tumor Immune Response by Reshaping the Tumor Microenvironment
Lead sponsor
Xijing Hospital
Phase
Observational
Overall status
Not yet recruiting
Start date
January 30, 2025
Completion date
June 1, 2026
Enrollment
450 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

bladder cancer, kidney cancer, prostate cancer